Bicara Therapeutics Inc. Common Stock (BCAX) Stock Price
BCAXStock
$24.58+99.16%52W
Market Cap$1.63B
P/E—
PEG Ratio—
Div yield—
Beta0.85
BCAX Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)51.49%
Price vs S&P 500 (4W)-15.33%
VGM Score69.32
BCAX Earnings Surprise History
Q2 25-0.50est. -0.54
Q3 25-0.67est. -0.53
Q4 25-0.68est. -0.65
Q1 26-0.93est. -0.65
Q2 26-0.82est. -0.83
BCAX Analyst Recommendations
May 2026
Jun 2026
Jul 2026
Aug 2026
4.10
4.14
4.14
4.14
Industry Peers — Pharmaceuticals(571)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
BCAXBicara Therapeutics Inc. Common Stock | — | — | B | $24.58 |
| LLYEli Lilly & Co. | D | B | B | $1233.66 |
| JNJJohnson & Johnson | D | C | B | $273.14 |
| ABBVABBVIE INC. | D | C | B | $265.79 |
| MRKMerck & Co., Inc. | D | C | A | $156.45 |
| NVSNovartis AG | C | C | C | $159.98 |
| AZNAstraZeneca PLC | C | B | C | $169.66 |
| NVONovo-Nordisk A/S | B | C | C | $48.66 |
| ABTAbbott Laboratories | C | C | B | $116.13 |
| PFEPfizer Inc. | C | D | C | $28.57 |
| VRTXVertex Pharmaceuticals Inc | D | C | B | $552.85 |
About Bicara Therapeutics Inc. Common Stock
Bicara Therapeutics is a clinical-stage biopharmaceutical company developing bifunctional antibody therapies for solid tumors. Its lead program, ficerafusp alfa, combines an EGFR-directed monoclonal antibody with a TGF-beta binding domain, targeting two clinically validated oncology pathways.